<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578862</url>
  </required_header>
  <id_info>
    <org_study_id>2015.131.A</org_study_id>
    <nct_id>NCT02578862</nct_id>
  </id_info>
  <brief_title>Total Intravenous Anesthesia in Sinus Surgery</brief_title>
  <official_title>Total Intravenous Versus Inhaled Anesthesia in Endoscopic Sinus Surgery for High-Grade Paranasal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Utilization of total intravenous anesthesia (TIVA) has been proposed as a method to improve
      visualization during endoscopic sinus surgery (ESS), largely due to its physiologic decrease
      in cardiac output without the peripheral smooth muscle relaxation and resultant vasodilation
      associated with inhaled anesthetics. This may be especially important in cases of advanced
      inflammatory sinus disease, when visualization may be most compromised. The goal of this
      study is to improve clinical practice paradigms by evaluating the use of TIVA versus inhaled
      anesthetic for maintenance of anesthesia in ESS for advanced paranasal sinus disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:

        1. Determine the effect of total intravenous versus inhaled anesthesia on intraoperative
           visual field in endoscopic sinus surgery for advanced paranasal sinus disease

        2. Evaluate clinical outcomes associated with choice of total intravenous versus inhaled
           anesthesia in endoscopic sinus surgery

      General Design:

      Double blind, randomized controlled trial of total intravenous versus inhaled anesthetic for
      maintenance of anesthesia during endoscopic sinus surgery.

      Subject Recruitment and Screening:

      Patients will be screened for study inclusion by the principal investigator (EDM) during
      their preoperative visit in the Department of Otolaryngology. Those meeting inclusion
      criteria will be introduced to the study at this time. A full description of the research
      purpose, personnel, procedures, risks and benefits will be presented, and a copy of the study
      consent documentation will be provided for home review.

      Method for Assigning Subjects to Treatment Groups:

      On the day of surgery, eligible participants will be admitted to the Day of Surgery
      Department, where a member of the Anesthesia team will review study information and confirm
      informed consent. A randomly assigned, sealed envelope will then be opened to assign
      participants to either the TIVA, or inhaled anesthetic cohort. At no time will the patient or
      surgeon be made aware of the patient's cohort.

      Blinding of Study Drug:

      At no time will the patient or surgeon be made aware of the patient's cohort. During the
      procedure the surgeon is blinded to the type of anesthesia by placement of a high drape at
      the head of the operative table. Study reviewers will be blinded to treatment arm without
      cohort assignment at time of review for determination of visual field score.

      Study Procedures:

      Participants make no clinic/hospital visits for purposes of study completion as all patient
      interaction limited to visits and surveys completed as part of routine clinical care. Clinic
      visits will include a baseline preoperative visit, and visits at 1 week, 4 weeks, and 10
      weeks after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative Visual Field Assessment</measure>
    <time_frame>Performed intraoperatively at the end of surgical case</time_frame>
    <description>Wormald Visualization Scale (validated)
Grade Assessment (0-10) -Higher scores indicate worsening visualization
0 No bleeding
1-2 points of ooze
3-4 points of ooze
5-6 points of ooze
7-8 points of ooze
9-10 points of ooze (sphenoid fills in 60 seconds)*
10 points of ooze, obscuring surface (sphenoid fills in 50 seconds)*
Mild bleeding/oozing from entire surgical surface with slow accumulation of blood in the post nasal space (sphenoid fills by 40 seconds)
Moderate bleeding from entire surgical surface with moderate accumulation of blood in the post nasal space at (sphenoid fills by 30 seconds)
Moderately severe bleeding with rapid accumulation of blood in the post nasal space (sphenoid fills by 20 seconds)
Severe bleeding with nasal cavity filling rapidly(sphenoid fills in10 seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sinus-related Quality of Life</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Sinonasal Outcomes Test (SNOT-22) (validated)- measures sinus symptoms. Minimum 0 Maximum 110. Higher scores indicate worse sinus symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Blood Loss</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Amount of blood loss (milliliters) during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Time</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Total time spent in surgery (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-anesthesia Care Unit Recovery Time</measure>
    <time_frame>Immediately following surgery (postoperative day zero)</time_frame>
    <description>Hours spent in post-anesthesia care unit post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Treated With Post-operative Anti-emetics</measure>
    <time_frame>24 hours following surgery completion</time_frame>
    <description>patients receiving medication for post-operative nausea and/or vomiting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Advanced Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Total Intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous propofol for maintenance of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Anesthetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled volatile anesthetic for maintenance of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Total Intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <arm_group_label>Inhaled Anesthetic</arm_group_label>
    <other_name>Isoflurane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing endoscopic sinus surgery

          -  Advanced inflammatory sinus disease, defined as allergic fungal sinusitis, chronic
             rhinosinusitis with nasal polyposis, chronic rhinosinusitis with eosinophilia, or
             rhinosinusitis with pan-sinus opacification (Lund-Mackay score &gt;12).

        Exclusion Criteria:

          -  Noninflammatory sinonasal disease

          -  Disease extending through the skull base or orbital wall

          -  American Society of Anesthesiologists Preoperative Health Status &gt;II

          -  Known non-pharmacologic coagulopathy (platelet &lt; 50000/mL, international normalized
             ratio &gt; 1.2)

          -  Preoperative anticoagulants within 7 days of surgery

          -  Allergy to one of the study medications

          -  Age under 18 years

          -  Non-English-speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward D McCoul, MD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ochsner Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <results_first_submitted>July 2, 2018</results_first_submitted>
  <results_first_submitted_qc>November 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2018</results_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>Edward Mccoul, MD</investigator_full_name>
    <investigator_title>Active Medical Staff</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02578862/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Total Intravenous</title>
          <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Anesthetic</title>
          <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unplanned unilateral procedure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Intravenous</title>
          <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Anesthetic</title>
          <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="20" upper_limit="77"/>
                    <measurement group_id="B2" value="55" lower_limit="25" upper_limit="81"/>
                    <measurement group_id="B3" value="51.5" lower_limit="35.3" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="21" upper_limit="56"/>
                    <measurement group_id="B2" value="28" lower_limit="19" upper_limit="53"/>
                    <measurement group_id="B3" value="29.1" lower_limit="25.9" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists (ASA) Physical Status</title>
          <description>ASA I A normal healthy patient ASA II A patient with mild systemic disease ASA III A patient with severe systemic disease ASA IV A patient with severe systemic disease that is a constant threat to life ASA V A moribund patient who is not expected to survive without the operation ASA VI A declared brain-dead patient whose organs are being removed for donor purposes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Factors</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Polyposis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tissue Eosinophilia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Fungal Rhinosinusitis (AFRS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspirin Exacerbated Respiratory Disease (AERD)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Assessments</title>
          <description>Lund Mackay Score- measures sinus opacification, Min 0 Max 24. Higher score indicates more opacification.
SNOT-22 Score (Sinonasal Outcome Test-22)- measures sinus symptoms. Min 0 Max 110. Higher score indicates worse symptoms.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Lund-Mackay Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="B2" value="15" lower_limit="13" upper_limit="20"/>
                    <measurement group_id="B3" value="14" lower_limit="13" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SNOT-22 Score (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="37" upper_limit="59"/>
                    <measurement group_id="B2" value="45.5" lower_limit="27" upper_limit="58"/>
                    <measurement group_id="B3" value="47" lower_limit="34" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Co-morbidities</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Systemic Hypertension</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reactive Airway Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Artery Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-sinus Dysrhythmias</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tobacco Use</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Obstructive Pulmonary Disease (COPD)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Vascular Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Visual Field Assessment</title>
        <description>Wormald Visualization Scale (validated)
Grade Assessment (0-10) -Higher scores indicate worsening visualization
0 No bleeding
1-2 points of ooze
3-4 points of ooze
5-6 points of ooze
7-8 points of ooze
9-10 points of ooze (sphenoid fills in 60 seconds)*
10 points of ooze, obscuring surface (sphenoid fills in 50 seconds)*
Mild bleeding/oozing from entire surgical surface with slow accumulation of blood in the post nasal space (sphenoid fills by 40 seconds)
Moderate bleeding from entire surgical surface with moderate accumulation of blood in the post nasal space at (sphenoid fills by 30 seconds)
Moderately severe bleeding with rapid accumulation of blood in the post nasal space (sphenoid fills by 20 seconds)
Severe bleeding with nasal cavity filling rapidly(sphenoid fills in10 seconds)</description>
        <time_frame>Performed intraoperatively at the end of surgical case</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Intravenous</title>
            <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Anesthetic</title>
            <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Visual Field Assessment</title>
          <description>Wormald Visualization Scale (validated)
Grade Assessment (0-10) -Higher scores indicate worsening visualization
0 No bleeding
1-2 points of ooze
3-4 points of ooze
5-6 points of ooze
7-8 points of ooze
9-10 points of ooze (sphenoid fills in 60 seconds)*
10 points of ooze, obscuring surface (sphenoid fills in 50 seconds)*
Mild bleeding/oozing from entire surgical surface with slow accumulation of blood in the post nasal space (sphenoid fills by 40 seconds)
Moderate bleeding from entire surgical surface with moderate accumulation of blood in the post nasal space at (sphenoid fills by 30 seconds)
Moderately severe bleeding with rapid accumulation of blood in the post nasal space (sphenoid fills by 20 seconds)
Severe bleeding with nasal cavity filling rapidly(sphenoid fills in10 seconds)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Frontal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.0" upper_limit="4.3"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.8" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ethmoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.1" upper_limit="4.3"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.3" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Sphenoethmoidal Recess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.7" upper_limit="4.3"/>
                    <measurement group_id="O2" value="4.8" lower_limit="3.7" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Choana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.3" upper_limit="3.3"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.2" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Frontal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.7" upper_limit="4.8"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.3" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ethmoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.7" upper_limit="4.3"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.3" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Sphenoethmoidal Recess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.3" upper_limit="4.3"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.0" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Choana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.3" upper_limit="3.7"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.7" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sinus-related Quality of Life</title>
        <description>Sinonasal Outcomes Test (SNOT-22) (validated)- measures sinus symptoms. Minimum 0 Maximum 110. Higher scores indicate worse sinus symptoms.</description>
        <time_frame>3 months and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Intravenous</title>
            <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Anesthetic</title>
            <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Sinus-related Quality of Life</title>
          <description>Sinonasal Outcomes Test (SNOT-22) (validated)- measures sinus symptoms. Minimum 0 Maximum 110. Higher scores indicate worse sinus symptoms.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="12.6" upper_limit="27.6"/>
                    <measurement group_id="O2" value="14.2" lower_limit="6.4" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="10.0" upper_limit="33.0"/>
                    <measurement group_id="O2" value="15.2" lower_limit="5.9" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative Blood Loss</title>
        <description>Amount of blood loss (milliliters) during surgery</description>
        <time_frame>At time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Intravenous</title>
            <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Anesthetic</title>
            <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Blood Loss</title>
          <description>Amount of blood loss (milliliters) during surgery</description>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200" lower_limit="100" upper_limit="450"/>
                    <measurement group_id="O2" value="300" lower_limit="200" upper_limit="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Time</title>
        <description>Total time spent in surgery (hours)</description>
        <time_frame>At time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Intravenous</title>
            <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Anesthetic</title>
            <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Time</title>
          <description>Total time spent in surgery (hours)</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.9" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.8" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-anesthesia Care Unit Recovery Time</title>
        <description>Hours spent in post-anesthesia care unit post-operatively</description>
        <time_frame>Immediately following surgery (postoperative day zero)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Intravenous</title>
            <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Anesthetic</title>
            <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Post-anesthesia Care Unit Recovery Time</title>
          <description>Hours spent in post-anesthesia care unit post-operatively</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Treated With Post-operative Anti-emetics</title>
        <description>patients receiving medication for post-operative nausea and/or vomiting</description>
        <time_frame>24 hours following surgery completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Intravenous</title>
            <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Anesthetic</title>
            <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Treated With Post-operative Anti-emetics</title>
          <description>patients receiving medication for post-operative nausea and/or vomiting</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Total Intravenous</title>
          <description>Intravenous propofol for maintenance of anesthesia
Propofol</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Anesthetic</title>
          <description>Inhaled volatile anesthetic for maintenance of anesthesia
Sevoflurane</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>By limiting study inclusion to Chronic Rhinosinusitis patients with bilateral nasal polyps and preoperative Lund-Mackay scores &gt;12, we limit the generalizability of study findings. Single-site design limits external validity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Edward D McCoul, MD, MPH</name_or_title>
      <organization>Ochsner Medical Center</organization>
      <phone>504-842-4080</phone>
      <email>edward.mccoul@ochsner.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

